184 related articles for article (PubMed ID: 37199415)
1. Six-month immune responses to mRNA-1273 vaccine in combination antiretroviral therapy treated late presenter people with HIV according to previous SARS-CoV-2 infection.
Augello M; Bono V; Rovito R; Tincati C; d'Arminio Monforte A; Marchetti G
AIDS; 2023 Aug; 37(10):1503-1517. PubMed ID: 37199415
[TBL] [Abstract][Full Text] [Related]
2. Robust Vaccine-Induced as Well as Hybrid B- and T-Cell Immunity across SARS-CoV-2 Vaccine Platforms in People with HIV.
Verburgh ML; van Pul L; Grobben M; Boyd A; Wit FWNM; van Nuenen AC; van Dort KA; Tejjani K; van Rijswijk J; Bakker M; van der Hoek L; Schim van der Loeff MF; van der Valk M; van Gils MJ; Kootstra NA; Reiss P
Microbiol Spectr; 2023 Jun; 11(3):e0115523. PubMed ID: 37166335
[TBL] [Abstract][Full Text] [Related]
3. Persistent memory despite rapid contraction of circulating T Cell responses to SARS-CoV-2 mRNA vaccination.
Taus E; Hofmann C; Ibarrondo FJ; Gong LS; Hausner MA; Fulcher JA; Krogstad P; Kitchen SG; Ferbas KG; Tobin NH; Rimoin AW; Aldrovandi GM; Yang OO
Front Immunol; 2023; 14():1100594. PubMed ID: 36860850
[TBL] [Abstract][Full Text] [Related]
4. Humoral and cellular immunity to SARS-COV-2 after vaccination with mRNA vaccines in PLWH with discordant immune response. Influence of the vaccine administered.
López-Cortés LF; Saborido-Alconchel A; Trujillo-Rodríguez M; Serna-Gallego A; Llaves-Flores S; Muñoz-Muela E; Pérez-Santos MJ; Lozano C; Mejias-Trueba M; Roca C; Espinosa N; Gutiérrez-Valencia A
Front Immunol; 2023; 14():1129753. PubMed ID: 37006309
[TBL] [Abstract][Full Text] [Related]
5. Long-term quantitative assessment of anti-SARS-CoV-2 spike protein immunogenicity (QUASI) after COVID-19 vaccination in older people living with HIV (PWH).
Tuan JJ; Zapata H; Barakat L; Andrews L; Behnegar A; Kim YW; Kayani J; Mutic S; Ryall L; Turcotte B; Critch-Gilfillan T; Zhao M; Salahuddin S; Gupta S; Sutton R; Friedland G; Emu B; Ogbuagu O
BMC Infect Dis; 2022 Sep; 22(1):744. PubMed ID: 36131232
[TBL] [Abstract][Full Text] [Related]
6. Kinetics and Persistence of the Cellular and Humoral Immune Responses to BNT162b2 mRNA Vaccine in SARS-CoV-2-Naive and -Experienced Subjects: Impact of Booster Dose and Breakthrough Infections.
Desmecht S; Tashkeev A; El Moussaoui M; Marechal N; Perée H; Tokunaga Y; Fombellida-Lopez C; Polese B; Legrand C; Wéry M; Mni M; Fouillien N; Toussaint F; Gillet L; Bureau F; Lutteri L; Hayette MP; Moutschen M; Meuris C; Vermeersch P; Desmecht D; Rahmouni S; Darcis G
Front Immunol; 2022; 13():863554. PubMed ID: 35711445
[TBL] [Abstract][Full Text] [Related]
7. Limited Humoral and Specific T-Cell Responses After SARS-CoV-2 Vaccination in PWH With Poor Immune Reconstitution.
Benet S; Blanch-Lombarte O; Ainsua-Enrich E; Pedreño-Lopez N; Muñoz-Basagoiti J; Raïch-Regué D; Perez-Zsolt D; Peña R; Jiménez E; de la Concepción MLR; Ávila C; Cedeño S; Escribà T; Romero-Martín L; Alarcón-Soto Y; Rodriguez-Lozano GF; Miranda C; González S; Bailón L; Blanco J; Massanella M; Brander C; Clotet B; Paredes R; Esteve M; Izquierdo-Useros N; Carrillo J; Prado JG; Moltó J; Mothe B
J Infect Dis; 2022 Nov; 226(11):1913-1923. PubMed ID: 36200261
[TBL] [Abstract][Full Text] [Related]
8. Humoral and Cellular Immune Response Elicited by mRNA Vaccination Against Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) in People Living With Human Immunodeficiency Virus Receiving Antiretroviral Therapy Based on Current CD4 T-Lymphocyte Count.
Antinori A; Cicalini S; Meschi S; Bordoni V; Lorenzini P; Vergori A; Lanini S; De Pascale L; Matusali G; Mariotti D; Cozzi Lepri A; Gallì P; Pinnetti C; Gagliardini R; Mazzotta V; Mastrorosa I; Grisetti S; Colavita F; Cimini E; Grilli E; Bellagamba R; Lapa D; Sacchi A; Marani A; Cerini C; Candela C; Fusto M; Puro V; Castilletti C; Agrati C; Girardi E; Vaia F;
Clin Infect Dis; 2022 Aug; 75(1):e552-e563. PubMed ID: 35366316
[TBL] [Abstract][Full Text] [Related]
9. Booster Vaccination Against SARS-CoV-2 Induces Potent Immune Responses in People With Human Immunodeficiency Virus.
Fidler S; Fox J; Tipoe T; Longet S; Tipton T; Abeywickrema M; Adele S; Alagaratnam J; Ali M; Aley PK; Aslam S; Balasubramanian A; Bara A; Bawa T; Brown A; Brown H; Cappuccini F; Davies S; Fowler J; Godfrey L; Goodman AL; Hilario K; Hackstein CP; Mathew M; Mujadidi YF; Packham A; Petersen C; Plested E; Pollock KM; Ramasamy MN; Robinson H; Robinson N; Rongkard P; Sanders H; Serafimova T; Spence N; Waters A; Woods D; Zacharopoulou P; Barnes E; Dunachie S; Goulder P; Klenerman P; Winston A; Hill AVS; Gilbert SC; Carroll M; Pollard AJ; Lambe T; Ogbe A; Frater J
Clin Infect Dis; 2023 Jan; 76(2):201-209. PubMed ID: 36196614
[TBL] [Abstract][Full Text] [Related]
10. Immunogenicity and tolerability of COVID-19 messenger RNA vaccines in primary immunodeficiency patients with functional B-cell defects.
Pham MN; Murugesan K; Banaei N; Pinsky BA; Tang M; Hoyte E; Lewis DB; Gernez Y
J Allergy Clin Immunol; 2022 Mar; 149(3):907-911.e3. PubMed ID: 34952033
[TBL] [Abstract][Full Text] [Related]
11. Persistent T cell-mediated immune responses against Omicron variants after the third COVID-19 mRNA vaccine dose.
Belik M; Liedes O; Vara S; Haveri A; Pöysti S; Kolehmainen P; Maljanen S; Huttunen M; Reinholm A; Lundberg R; Skön M; Österlund P; Melin M; Hänninen A; Hurme A; Ivaska L; Tähtinen PA; Lempainen J; Kakkola L; Jalkanen P; Julkunen I
Front Immunol; 2023; 14():1099246. PubMed ID: 36756112
[TBL] [Abstract][Full Text] [Related]
12. Real-world serological responses to extended-interval and heterologous COVID-19 mRNA vaccination in frail, older people (UNCoVER): an interim report from a prospective observational cohort study.
Vinh DC; Gouin JP; Cruz-Santiago D; Canac-Marquis M; Bernier S; Bobeuf F; Sengupta A; Brassard JP; Guerra A; Dziarmaga R; Perez A; Sun Y; Li Y; Roussel L; Langelier MJ; Ke D; Arnold C; Whelan M; Pelchat M; Langlois MA; Zhang X; Mazer BD;
Lancet Healthy Longev; 2022 Mar; 3(3):e166-e175. PubMed ID: 35224524
[TBL] [Abstract][Full Text] [Related]
13. Characterization of SARS-CoV-2-Specific Humoral and Cellular Immune Responses Induced by Inactivated COVID-19 Vaccines in a Real-World Setting.
Li Z; Xiang T; Liang B; Deng H; Wang H; Feng X; Quan X; Wang X; Li S; Lu S; Yang X; Wang B; Zelinskyy G; Trilling M; Sutter K; Lu M; Dittmer U; Yang D; Zheng X; Liu J
Front Immunol; 2021; 12():802858. PubMed ID: 35003131
[TBL] [Abstract][Full Text] [Related]
14. Humoral and Cellular Immune Responses to Vector, Mix-and-Match, or mRNA Vaccines against SARS-CoV-2 and the Relationship between the Two Immune Responses.
Nam M; Yun SG; Kim SW; Kim CG; Cha JH; Lee C; Kang S; Park SG; Kim SB; Lee KB; Chung YS; Nam MH; Lee CK; Cho Y
Microbiol Spectr; 2022 Aug; 10(4):e0249521. PubMed ID: 35946811
[TBL] [Abstract][Full Text] [Related]
15. Kinetics of the B- and T-Cell Immune Responses After 6 Months From SARS-CoV-2 mRNA Vaccination in Patients With Rheumatoid Arthritis.
Farroni C; Picchianti-Diamanti A; Aiello A; Nicastri E; Laganà B; Agrati C; Castilletti C; Meschi S; Colavita F; Cuzzi G; Casetti R; Grassi G; Petrone L; Vanini V; Salmi A; Repele F; Altera AMG; Maffongelli G; Corpolongo A; Salemi S; Di Rosa R; Nalli G; Sesti G; Vaia F; Puro V; Goletti D
Front Immunol; 2022; 13():846753. PubMed ID: 35309297
[TBL] [Abstract][Full Text] [Related]
16. Humoral- and T-Cell-Specific Immune Responses to SARS-CoV-2 mRNA Vaccination in Patients With MS Using Different Disease-Modifying Therapies.
Tortorella C; Aiello A; Gasperini C; Agrati C; Castilletti C; Ruggieri S; Meschi S; Matusali G; Colavita F; Farroni C; Cuzzi G; Cimini E; Tartaglia E; Vanini V; Prosperini L; Haggiag S; Galgani S; Quartuccio ME; Salmi A; Repele F; Altera AMG; Cristofanelli F; D'Abramo A; Bevilacqua N; Corpolongo A; Puro V; Vaia F; Capobianchi MR; Ippolito G; Nicastri E; Goletti D;
Neurology; 2022 Feb; 98(5):e541-e554. PubMed ID: 34810244
[TBL] [Abstract][Full Text] [Related]
17. Predominantly defective CD8
Taus E; Shino MY; Ibarrondo FJ; Hausner MA; Hofmann C; Yang OO
J Transl Med; 2023 Jun; 21(1):374. PubMed ID: 37291575
[TBL] [Abstract][Full Text] [Related]
18. SARS-CoV2 wild type and mutant specific humoral and T cell immunity is superior after vaccination than after natural infection.
Richardson JR; Götz R; Mayr V; Lohse MJ; Holthoff HP; Ungerer M
PLoS One; 2022; 17(4):e0266701. PubMed ID: 35468147
[TBL] [Abstract][Full Text] [Related]
19. Antibody response after two doses of homologous or heterologous SARS-CoV-2 vaccines in healthcare workers at health promotion centers: A prospective observational study.
Nah EH; Cho S; Park H; Kim S; Noh D; Kwon E; Cho HI
J Med Virol; 2022 Oct; 94(10):4719-4726. PubMed ID: 35655438
[TBL] [Abstract][Full Text] [Related]
20. T-cell responses induced by ChAdOx1 nCoV-19 (AZD1222) vaccine to wild-type severe acute respiratory syndrome coronavirus 2 among people with and without HIV in South Africa.
McMahon WC; Kwatra G; Izu A; Koen AL; Greffrath J; Fairlie L; Patel F; Mukendi CK; Mbele NJ; Lala R; Burgers WA; Nunes MC; Cutland CL; Gilbert SC; Lambe T; Pollard AJ; Madhi SA
AIDS; 2023 Jan; 37(1):105-112. PubMed ID: 36476455
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
